Free Trial
ETR:BAYN

Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

€28.91
-0.07 (-0.24%)
(As of 09/6/2024 ET)
Today's Range
€28.91
€29.89
50-Day Range
€25.32
€29.09
52-Week Range
€24.96
€51.32
Volume
4.20 million shs
Average Volume
N/A
Market Capitalization
$28.40 billion
P/E Ratio
N/A
Dividend Yield
0.38%
Price Target
N/A
BAYN stock logo

About Bayer Aktiengesellschaft Stock (ETR:BAYN)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

BAYN Stock Price History

BAYN Stock News Headlines

Bayer: Speculative Value Beyond Litigation Pressures
Bayer AG Aktie: Kursanstieg nach Analystenoptimismus
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Bayer Aktiengesellschaft (ETR:BAYN) Stock Price Down 0.8%
Aktie dreht: Bayer: Bedeutender Meilenstein!
Bayer startet Phase-III-Studie mit Lungenkrebsmittel
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Aktien»Nachrichten»BAYER AKTIE»DAX-Feier ohne Bayer
Bayer Aktiengesellschaft (1BAYN.MI)
Bayer Aktie: Der große Traum geplatzt?
Bayer-Aktie: Fehlschlag auf ganzer Linie
Minimaler Kursabschlag bei der Bayer-Aktie (28,15 €)
Bayer streicht in Basel 150 Stellen
Bayer AG Aktie: Kurseinbruch trotz Rallychancen
See More Headlines
Receive BAYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
96,931
Year Founded
N/A

Profitability

Net Income
$-1,270,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$47.11 billion
Cash Flow
€5.05 per share
Book Value
€36.33 per share

Miscellaneous

Free Float
N/A
Market Cap
$28.40 billion
Optionable
Not Optionable
Beta
0.97
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. William N. Anderson (Age 58)
    Chairman of the Management Board & CEO
    Comp: $8.43M
  • Mr. Wolfgang U. Nickl (Age 55)
    CFO & Member of Management Board
    Comp: $1.98M
  • Mr. Heiko W. J. Schipper (Age 55)
    Member of Management Board & President of the Consumer Health Division
    Comp: $1.95M
  • Mr. Stefan Oelrich (Age 56)
    Head of the Pharmaceuticals Division & Member of the Board of Management
    Comp: $1.95M
  • Mr. Rodrigo Santos (Age 51)
    Member of Management Board & President of the Crop Science Division
    Comp: $2.17M
  • Ms. Heike Prinz (Age 60)
    Chief Talent Officer, Labor Director & Member of Management Board
    Comp: $1.33M
  • Mr. Julio Triana (Age 58)
    Member of Management Board & President of Consumer Health Division
  • Dr. Sebastian Guth Ph.D.
    Chief Operating Officer
  • Dr. Jost Reinhard (Age 52)
    Head of Investor Relations
  • Mr. Michael Preuss
    Head of Communications, Government Relations and Corporate Brand

Should I Buy Bayer Aktiengesellschaft Stock? BAYN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Bayer Aktiengesellschaft:

  • Recent developments show Bayer Aktiengesellschaft has a strong focus on innovation and research in the life science industry.
  • Bayer Aktiengesellschaft's current stock price is competitive and shows potential for growth.
  • The company has reported high annual revenue figures, indicating a strong financial performance.
  • Net income for Bayer Aktiengesellschaft has been consistently positive, showcasing financial stability.
  • Bayer Aktiengesellschaft has a diverse portfolio across Pharmaceuticals, Consumer Health, and Crop Science segments, reducing risk exposure.

Cons

Investors should be bearish about investing in Bayer Aktiengesellschaft for these reasons:

  • Bay National Corp., a bank holding company, may cause confusion for investors researching Bayer Aktiengesellschaft due to similar names.
  • While Bayer Aktiengesellschaft has a diverse portfolio, this could also lead to challenges in managing different business segments effectively.
  • Market competition in the life science industry is intense, which could impact Bayer Aktiengesellschaft's market share and profitability.
  • Fluctuations in global economic conditions may affect Bayer Aktiengesellschaft's performance, especially in the pharmaceutical sector.
  • Regulatory changes and legal challenges in the healthcare and agriculture sectors could pose risks to Bayer Aktiengesellschaft's operations.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 26, 2024. Please send any questions or comments about these Bayer Aktiengesellschaft pros and cons to contact@marketbeat.com.

BAYN Stock Analysis - Frequently Asked Questions

How have BAYN shares performed this year?

Bayer Aktiengesellschaft's stock was trading at €33.63 on January 1st, 2024. Since then, BAYN stock has decreased by 14.0% and is now trading at €28.91.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Bayer Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Lam Research (LRCX), QUALCOMM (QCOM) and SAP (SAP).

This page (ETR:BAYN) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners